Brazil Seeks Expanded Access to Gilead's Lenacapavir for HIV Prevention

Brazil is lobbying for improved access and pricing for Gilead Sciences' twice-yearly injectable HIV prevention drug, lenacapavir, citing slow rollout in Latin America. The initiative highlights ongoing tensions between public health needs in middle-income nations and pharmaceutical patent-protected distribution models. It remains uncertain whether Gilead will adjust its tiered pricing or licensing strategy to accommodate Brazil's specific market requirements.